Recurrent Disease

GTD is a highly curable disease. Women with hydatidiform mole have an excellent prognosis and women with malignant GTD (called GTN) usually have a very good prognosis. Choriocarcinoma, for example, is an uncommon, yet almost always curable cancer. Although choriocarcinoma is a highly malignant tumor and life-threatening disease, it is very sensitive to chemotherapy. 85-90% of women with low-risk malignant GTD are cured by the initial chemotherapy and the remaining are cured by the use of stronger combinations of drugs or surgery. Similarly, 85-90% of women who develop high-risk malignant GTD are cured by chemotherapy used together with the selective use of surgery and radiation. Approximately 10-15% of women with high-risk malignant GTD will develop drug resistance after prolonged chemotherapy. This group is made up of patients with stage IV disease that involves distant organs such as the brain, liver and bowel. Specially designed chemotherapy treatments using drugs that have been shown to be effective against other cancers are being employed to prolong life for many of these women.


September is Gynecologic Cancer Awareness Month.


Read the 2015 Fact Sheet: The Role of Heredity in Gynecologic Cancer


The Foundation is featured in the Sept. issues of Coping, Women and Family Circle magazines. Look out for our articles & ads!


Research Prize applications are due 10/28. Click here to apply for one of the 7 available prizes.


The next Ovarian Cancer Survivors Course is Nov. 7 in Washington, D.C. For more information, click here.